CytomX Therapeutics Posts 402% Return Over the Last Year, Analysts Warn of Potential Risks

CytomX Therapeutics' investors have seen a 402% return in the last year. The company's earnings per share grew by 44%, but the share price gain far exceeded that. The CEO is modestly remunerated, but it's essential to assess the company's future earnings growth potential. The total shareholder return over one year is impressive, but the TSR loss over five years raises concerns. It's crucial to consider risks, such as those highlighted by 3 warning signs for CytomX Therapeutics.